PMID- 23170259
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211021
IS  - 2162-4011 (Print)
IS  - 2162-402X (Electronic)
IS  - 2162-4011 (Linking)
VI  - 1
IP  - 7
DP  - 2012 Oct 1
TI  - Trial watch: Dendritic cell-based interventions for cancer therapy.
PG  - 1111-1134
AB  - Dendritic cells (DCs) occupy a central position in the immune system, 
      orchestrating a wide repertoire of responses that span from the development of 
      self-tolerance to the elicitation of potent cellular and humoral immunity. 
      Accordingly, DCs are involved in the etiology of conditions as diverse as 
      infectious diseases, allergic and autoimmune disorders, graft rejection and 
      cancer. During the last decade, several methods have been developed to load DCs 
      with tumor-associated antigens, ex vivo or in vivo, in the attempt to use them as 
      therapeutic anticancer vaccines that would elicit clinically relevant immune 
      responses. While this has not always been the case, several clinical studies have 
      demonstrated that DC-based anticancer vaccines are capable of activating 
      tumor-specific immune responses that increase overall survival, at least in a 
      subset of patients. In 2010, this branch of clinical research has culminated with 
      the approval by FDA of a DC-based therapeutic vaccine (sipuleucel-T, Provenge((R))) 
      for use in patients with asymptomatic or minimally symptomatic metastatic 
      hormone-refractory prostate cancer. Intense research efforts are currently 
      dedicated to the identification of the immunological features of patients that 
      best respond to DC-based anticancer vaccines. This knowledge may indeed lead to 
      personalized combination strategies that would extend the benefit of DC-based 
      immunotherapy to a larger patient population. In addition, widespread enthusiasm 
      has been generated by the results of the first clinical trials based on in vivo 
      DC targeting, an approach that holds great promises for the future of DC-based 
      immunotherapy. In this Trial Watch, we will summarize the results of recently 
      completed clinical trials and discuss the progress of ongoing studies that have 
      evaluated/are evaluating DC-based interventions for cancer therapy.
FAU - Galluzzi, Lorenzo
AU  - Galluzzi L
AD  - Universite Paris Descartes/Paris V; Sorbonne Paris Cite; Paris, France ; Institut 
      Gustave Roussy; Villejuif, France.
FAU - Senovilla, Laura
AU  - Senovilla L
FAU - Vacchelli, Erika
AU  - Vacchelli E
FAU - Eggermont, Alexander
AU  - Eggermont A
FAU - Fridman, Wolf Herve
AU  - Fridman WH
FAU - Galon, Jerome
AU  - Galon J
FAU - Sautes-Fridman, Catherine
AU  - Sautes-Fridman C
FAU - Tartour, Eric
AU  - Tartour E
FAU - Zitvogel, Laurence
AU  - Zitvogel L
FAU - Kroemer, Guido
AU  - Kroemer G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Oncoimmunology
JT  - Oncoimmunology
JID - 101570526
PMC - PMC3494625
EDAT- 2012/11/22 06:00
MHDA- 2012/11/22 06:01
PMCR- 2012/10/01
CRDT- 2012/11/22 06:00
PHST- 2012/11/22 06:00 [entrez]
PHST- 2012/11/22 06:00 [pubmed]
PHST- 2012/11/22 06:01 [medline]
PHST- 2012/10/01 00:00 [pmc-release]
AID - 2012ONCOIMM0240 [pii]
AID - 10.4161/onci.21494 [doi]
PST - ppublish
SO  - Oncoimmunology. 2012 Oct 1;1(7):1111-1134. doi: 10.4161/onci.21494.